SlideShare uma empresa Scribd logo
1 de 34
Baixar para ler offline
Depressive Illness

Asad Tamizuddin Nizami
Assistant Professor
Institute of Psychiatry
Rawalpindi Medical College
Major Depressive Episode
A marked change from previous functioning for at least two
weeks with 5 or more of the following symptoms:

▫
▫
▫
▫
▫
▫
▫
▫
▫

Depressed Mood (Irritability/anger in adolescents)
Markedly diminished interest or pleasure
Significant change in appetite and/or weight
Insomnia or hypersomnia
Psychomotor agitation or retardation
Fatigue or loss of energy
Feelings of worthlessness or excessive guilt
Diminished concentration
Recurrent thoughts of death
Epidemiology
• Depression is the fourth most important contributor to the global
burden of disease
• The point prevalence for depression is 1.9% for males and 3.2% for
females.
• 5.8% of males and 9.5% of females will develop a depressive episode
within a 12-month period.
• Every year 5-8% of the adult population gets a depression .
• Lifetime risk for a severe depression amounts to 12-16%.

Marianne C. Kastrup, Armando Báez Ramos . Global mental health- secondary publication
Danish Medical Bulletin - No. 1. February 2007. Vol. 54 Pages 42-3
In Pakistan………….

R a n d o m C o m m u n it y S a m p le
3 3 .6 2 %
M en
W om en
1 0 % (M u m fo rd 2 0 0 0 )- 3 3 % (J a v e d 1 9 9 4 ) 2 8 .8 % (R a b b a n i ) - 6 6 % (M u m fo rd 1 9 9 7 )
Percentage of major diagnostic
categories during four years in IOP
journal of CPSP (2001)
Etiology of Depression - Genetics
• Indirect evidence suggests that the glycogen synthase kinase-3beta
(GSK3beta) gene might be implicated in major depressive disorder
(MDD). A recent study identified a link between the GSK3 beta
polymorphism and the structural brain changes in major depressive
disorder.(2)
• A meta-analysis yielded little evidence that the serotonin
transporter genotype alone or in interaction with stressful life
events was associated with an elevated risk of depression in men
alone, women alone, or in both sexes combined.(3)
•

•

2. Inkster B et al. Association of GSK3Beta polymorphism with structural brain changes in major depressive disorder. Arch
Gen Psychiatry. 2009 Jul;66(7):721-8.
3. Risch N et al. JAMA. 2009 Jun 17;301(23):2462-71. Interaction between the serotonin transporter gene (5-HTTLPR),
stressful life events, and risk of depression: a meta-analysis.
Neurobiology
• In recent years the monoamine theory of depression has given way
to a molecular and cellular theory that suggests that
antidepressants work by increase in brain levels of neurotrophic
factors such as brain-derived neurotrophic factor (BDNF).
• Basic laboratory work has documented the importance of
neurotrophins in neuronal survival and synaptic plasticity.which
lead to structural brain changes i.e hippocampal atrophy seen in
depression(1)
Dan J. Stein, Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of
Psychopathology
Neurobiology
• BNDF plays a role in a range of neurodegenerative,
neuroinflammatory, and neurodevelopmental disorders, as well as
in some psychiatric and substance use disorders.
• Decreased hippocampal BDNF mRNA and cell atrophy are, for
example, seen in several animal models of depression.
• Depression is associated with decreased hippocampal volume, and
depressed patients have decreased hippocampal BDNF.
• Chronic stress leads to hippocampal cell loss and to downregulation of BDNF
Dan J. Stein, Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of
Psychopathology
Interestingly…………..
• In general practice 1 in 5 new consultations are for pain
symptoms for which no specific cause is found.

• The pain symptoms of 1/3 of all patients seen in medical
clinics remain medically unexplained at the time of
discharge.
•
•
•
•
•
•

Research has indicated
34% of patients with joint or limb pain,
38% of patients with back pain,
40% of patients with headache,
46% of patients with chest pain, and
43% of patients with abdominal pain
had Depression.

Kroenke K, Spitzer RL, Williams JB, et al. Arch Fam Med. 1994;3:774-779.
In primary care, physical symptoms are often the chief complaint in
depressed patients

In one study 69% of
diagnosed
depressed patients
reported
unexplained
physical symptoms
as their chief
compliant1
N = 1146 Primary care patients with major depression

1. Simon GE, et al. N Engl J Med. 1999;341(18):1329-1335.
Is there a connection between pain & depression……..
• There is a Neurochemical overlapping in the phenomena
of pain complaints and depression.
• Serotonin (or 5-HT) and norepinephrine have emerged as
2 neurotransmitters that are involved in both pain and
depression.
Both serotonin and nor epinephrine mediate a broad spectrum of
depressive symptoms

Serotonin (5-HT)

Depressed
Mood

Norepinephrine (NE)

Sex

Anxiety

Concentration

Appetite

Vague Aches
and pain

Interest

Aggression

Irritability

Motivation

Thought
process

References:
1. Adapted from: Stahl SM. In: Essential Psychopharmacology:
Neuroscientific Basis and Practical Applications: 2nd ed. Cambridge
University Press 2000.

2. Blier P, et al. J Psychiatry Neurosci. 2001;26(1):37-43.
3. Doraiswamy PM. J Clin Psychiatry. 2001;62(suppl 12):30-35.
4. Verma S, et al. Int Rev Psychiatry. 2000;12:103-114.
Serotonin5HT and Nor epinephrineNE in the brain
Limbic System
Prefrontal
Cortex

Raphe Nuclei
(5-HT source)

Cooper JR, Bloom FE. The Biochemical Basis of Neuropharmacology. 1996.

Locus Ceruleus
(NE Source)
• Dysregulation of Serotonin (5HT)
and Norepinephrine (NE) in the
brain are strongly associated with
depression
• Dysregulation of 5HT and NE in the
spinal cord may explain an
increased pain perception among
depressed patients1-3
• Imbalances of 5HT and NE may
explain the presence of both
emotional and physical symptoms
of depression.
Adapted from References:
1. Stahl SM. J. Clin Psych. 2002;63:203-220.
2. Verma S, et al. Int Rev Psychiatry. 2000;12:103-114.
3. Blier P, et al. J Psychiatry Neurosci. 2001;26(1):37-43.

Descending Pathway
Descending
Pathway

Ascending
Pathway

Ascending
Pathway
Research suggests that unexplained pain can be
the best indicator of depression, especially among
the elderly.
Stewart RB, Blashfield R, Hale WE, et al. J Fam Pract. 1991;32:497-502.
Ongoing untreated somatic depression lead to
structural changes in the central nervous system
and augments the risk of persistent pain’’
Areas of the brain which are involved in memory
and decision making undergo structural changes
due to stress, which cause long term imbalances in
hormonal regulation”
• Hippocampus
• Prefrontal cortex
• Amygdala
Undergo changes in
size and function in
depression
• Dentate gyrus continues
to produce new neurons
in adult life
• this is suppressed by
acute and chronic stress
and
• restored by
antidepressant treatment
The loss of neurons in hippocampus due to
stress is reversible if the stress is terminated at
the end of 3 weeks
Stress also suppresses neurogenesis and causes
dendritic shrinkage
Comorbid Mood and Anxiety Disorders
Lifetime Comorbidity
of Patients with PTSD1 48%

to 65% of Patients 50%
with Panic Disorder2

Posttraumatic
Stress Disorder

Social Phobia

Panic Disorder

Major
Depression

GAD

(Social Anxiety Disorder)

OCD
of Patients with 34-70%
Social Phobia4,6

of 39%-8%
Patients with GAD5

of Patients 67%
with OCD3

Kessler et al. Arch Gen Psychiatry, 1995 2. DSM-IV 3. Rasmussen.. 1
Psychopharmacol Bull, 1988 4. Van Ameringen et al. J Affect Disord, 1991 5.
Brawman-Mintzer, Lydiard RB. J Clin Psychiatry, 1996 6. Stein et al, Am J
Psychiatry, 2000
Aims Of Treatment

TREATMENT

REDUCE SIGNS,
SYMPTOMS
RESTORE
ROLE
FUNCTION

MINIMIZE
RELAPSE/RECURREN
CE RISK
Treatment Options
• Antidepressants
• Combination Therapies
• Psychotherapy
• ECT
STEPS: Antidepressant Selection
• Safety
Drug-drug interaction potential
• Tolerability
Acute and long term
• Efficacy
Onset of action
Treatment and prophylaxis
• Payment
Cost-effectiveness
• Simplicity
Dosing
Need for monitoring
Antidepressants Groups
• TCAs : Amitriptyline, Doxepine, Trimipramine,
Clomipramine and other.
• SSRI : Fluvoxamine, Fluoxetine, Paroxetine,
Sertraline, Citalopram, Escitalopram
• RIMA :(Reversible inhibitor of MAO type A)
Moclobemide
• SNRI : (Reuptake inhibition of NA/5-HT )
Venlafaxine
Antidepressants Groups
• NaSSA : (5-HT2 and 5-HT3 antagonist,H1 antagonist.)
Mirtazapine
• DSA : (5-HT2 antagonist and 5-HT reuptake inhibitor)
Nefazodone
• NARI (SNRI) : (Selective NA reuptake inhibitor)
Reboxetine
Adverse events—a significant cause of
treatment discontinuation

Poor tolerability in early therapy

Drop out of SSRI therapy

Lin EHB et al. Medical Care 1995; 33:67–74.
Maddox JC et al. J Psychopharmacol 1994; 8:48–53.
Early drop out – other evidence
• Early drop out is common among patients taking antidepressants:

▫ 28% by week 4*
▫ 43% by week 8*
▫ 52% by week 12*

* Maddox JC et al. J Psychopharmacol 1994; 8:48-53
Adverse Events Are A Major Cause of Early
Dropout with SSRI Treatment

Most common early adverse events resulting in dropouts (> 5%)
Nausea

Headache

Anxiety

Drowsiness

N = 672; SSRIs included paroxetine or fluoxetine
Bull SA, et al. Ann Pharmacother. 2002;36:578–584.
Nausea is one of the most common side
effects
• SSRIs have been associated with early GI adverse
events, resulting in:
▫ poor compliance
▫ compromised long-term efficacy
▫ premature termination of treatment1,2

• Nausea is a leading cause of premature treatment
discontinuation for the SSRIs and serotonin norepinephrine
reuptake inhibitors3
• Clinical trials in major depression with paroxetine IR (n = 6145)
▫ most common event associated with withdrawal on paroxetine IR was
nausea (3.2% vs. 1.1% on placebo).

• Paroxetine CR was developed to minimise early-onset
nausea through a shifting of the drug absorption site
(lower in GI tract)
1 Lin EHB et al. Medical Care 1995; 33:67–74.
2 Maddox JC et al. J Psychopharmacol 1994; 8:48–53.
3 Golden RN et al. J Clin Psychiatry 2002; 63:577-584
Summary
• Patients have a high rate of non-adherence with
SSRIs due to adverse events
• First few weeks of therapy are critical
• Monitor medication compliance during this time
period
• Choose a medication that is effective and
generally well tolerated across multiple
indications
Role of Psychotherapy?
•

Psychotherapy either alone or in combination with
medication, has been shown to be effective in the
treatment of comorbid pain and depression

•

Some studies have found that the combination of medical
and psychotherapeutic treatments provides better results
than medication alone.
Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Arch Gen Psychiatry. 1984;41:33-41.
Thank you

Mais conteúdo relacionado

Mais procurados

Neuropsychiatric sequelae of stroke
Neuropsychiatric sequelae of strokeNeuropsychiatric sequelae of stroke
Neuropsychiatric sequelae of strokeDr. Sunil Suthar
 
Long acting antipsychotics
Long acting antipsychoticsLong acting antipsychotics
Long acting antipsychoticsDr.Jeet Nadpara
 
Major depressive disorder powerpoint
Major depressive disorder powerpointMajor depressive disorder powerpoint
Major depressive disorder powerpointbdoesnotforget
 
Major depressive disorder (MDD) presentation
Major depressive disorder (MDD) presentationMajor depressive disorder (MDD) presentation
Major depressive disorder (MDD) presentationDryogeshcsv
 
Consultation liaison psychiatry
Consultation liaison psychiatryConsultation liaison psychiatry
Consultation liaison psychiatryPriyash Jain
 
Mood disorders DSM 5 and ICD 11
Mood disorders DSM 5 and ICD 11 Mood disorders DSM 5 and ICD 11
Mood disorders DSM 5 and ICD 11 Simmi Waraich
 
Neuropsychiatric aspects of traumatic brain injury
Neuropsychiatric aspects of traumatic brain injuryNeuropsychiatric aspects of traumatic brain injury
Neuropsychiatric aspects of traumatic brain injuryAzfer Ibrahim
 
Major Depressive Disorder
Major Depressive Disorder Major Depressive Disorder
Major Depressive Disorder Usman Amin
 
Treatment resistant schizophrenia & Treatment resistant depression
Treatment resistant schizophrenia & Treatment resistant depressionTreatment resistant schizophrenia & Treatment resistant depression
Treatment resistant schizophrenia & Treatment resistant depressionEnoch R G
 
mood disorders
mood disordersmood disorders
mood disordersspurthi87
 
Major depressive disorder and its treatment
Major depressive disorder and its treatmentMajor depressive disorder and its treatment
Major depressive disorder and its treatmentAmruta Vaidya
 
Post stroke psychiatric symptoms
Post stroke psychiatric symptomsPost stroke psychiatric symptoms
Post stroke psychiatric symptomsSusanth Mj
 
Psychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseasePsychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseaseSoumen Karmakar
 
Depression vsk
Depression vskDepression vsk
Depression vsk9665388461
 

Mais procurados (20)

Neuropsychiatric sequelae of stroke
Neuropsychiatric sequelae of strokeNeuropsychiatric sequelae of stroke
Neuropsychiatric sequelae of stroke
 
Depression
DepressionDepression
Depression
 
Long acting antipsychotics
Long acting antipsychoticsLong acting antipsychotics
Long acting antipsychotics
 
Major depressive disorder powerpoint
Major depressive disorder powerpointMajor depressive disorder powerpoint
Major depressive disorder powerpoint
 
What is schizophrenia
What is schizophreniaWhat is schizophrenia
What is schizophrenia
 
Major depressive disorder (MDD) presentation
Major depressive disorder (MDD) presentationMajor depressive disorder (MDD) presentation
Major depressive disorder (MDD) presentation
 
Consultation liaison psychiatry
Consultation liaison psychiatryConsultation liaison psychiatry
Consultation liaison psychiatry
 
Mood disorders DSM 5 and ICD 11
Mood disorders DSM 5 and ICD 11 Mood disorders DSM 5 and ICD 11
Mood disorders DSM 5 and ICD 11
 
Neuropsychiatric aspects of traumatic brain injury
Neuropsychiatric aspects of traumatic brain injuryNeuropsychiatric aspects of traumatic brain injury
Neuropsychiatric aspects of traumatic brain injury
 
Major Depressive Disorder
Major Depressive Disorder Major Depressive Disorder
Major Depressive Disorder
 
Treatment resistant schizophrenia & Treatment resistant depression
Treatment resistant schizophrenia & Treatment resistant depressionTreatment resistant schizophrenia & Treatment resistant depression
Treatment resistant schizophrenia & Treatment resistant depression
 
mood disorders
mood disordersmood disorders
mood disorders
 
Major depressive disorder and its treatment
Major depressive disorder and its treatmentMajor depressive disorder and its treatment
Major depressive disorder and its treatment
 
Post stroke psychiatric symptoms
Post stroke psychiatric symptomsPost stroke psychiatric symptoms
Post stroke psychiatric symptoms
 
Depression
DepressionDepression
Depression
 
Depression
DepressionDepression
Depression
 
Psychotic disorders
Psychotic disordersPsychotic disorders
Psychotic disorders
 
Psychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseasePsychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's Disease
 
Depression
DepressionDepression
Depression
 
Depression vsk
Depression vskDepression vsk
Depression vsk
 

Semelhante a Depression-2010

MAJOR DEPRESSIVE DISORDER
MAJOR DEPRESSIVE DISORDERMAJOR DEPRESSIVE DISORDER
MAJOR DEPRESSIVE DISORDERVln Sekhar
 
Introduction to depression and antidepressant agents
Introduction to depression and antidepressant agentsIntroduction to depression and antidepressant agents
Introduction to depression and antidepressant agentsDomina Petric
 
Hanipsych, functional recovery in depression
Hanipsych, functional recovery in depressionHanipsych, functional recovery in depression
Hanipsych, functional recovery in depressionHani Hamed
 
MRCPsych Year 1 depression lecture sept 2013
MRCPsych Year 1 depression lecture sept 2013MRCPsych Year 1 depression lecture sept 2013
MRCPsych Year 1 depression lecture sept 2013Nick Stafford
 
Hanipsych, biology of depression
Hanipsych, biology of depressionHanipsych, biology of depression
Hanipsych, biology of depressionHani Hamed
 
Hanipsych, pain & dep
Hanipsych, pain & depHanipsych, pain & dep
Hanipsych, pain & depHani Hamed
 
Considerazioni sulla terapia farmacologica per l'insonnia
Considerazioni sulla terapia farmacologica per l'insonniaConsiderazioni sulla terapia farmacologica per l'insonnia
Considerazioni sulla terapia farmacologica per l'insonniaMerqurioEditore_redazione
 
Depression in community
Depression in communityDepression in community
Depression in communityDr Pradip Mate
 
Henderson depression update incl tms
Henderson   depression update incl tmsHenderson   depression update incl tms
Henderson depression update incl tmsLouis Cady, MD
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarNick Stafford
 
Different faces of depression
Different faces of depressionDifferent faces of depression
Different faces of depressionDr. Rakesh Mehta
 
The pharmacology of anti-depressants
The pharmacology of anti-depressants The pharmacology of anti-depressants
The pharmacology of anti-depressants Priyansha Singh
 
Treatment approach to resistant depression
Treatment approach to resistant depressionTreatment approach to resistant depression
Treatment approach to resistant depressionDr. Rakesh Mehta
 
Bipolar disorder mrc psych
Bipolar disorder mrc psychBipolar disorder mrc psych
Bipolar disorder mrc psychWalk KD
 
Hanipsych, resistant depression
Hanipsych, resistant depressionHanipsych, resistant depression
Hanipsych, resistant depressionHani Hamed
 
Case # 29- The depressed man who thought he was out of options. .docx
Case # 29- The depressed man who thought he was out of options. .docxCase # 29- The depressed man who thought he was out of options. .docx
Case # 29- The depressed man who thought he was out of options. .docxannandleola
 

Semelhante a Depression-2010 (20)

MAJOR DEPRESSIVE DISORDER
MAJOR DEPRESSIVE DISORDERMAJOR DEPRESSIVE DISORDER
MAJOR DEPRESSIVE DISORDER
 
Introduction to depression and antidepressant agents
Introduction to depression and antidepressant agentsIntroduction to depression and antidepressant agents
Introduction to depression and antidepressant agents
 
Hanipsych, functional recovery in depression
Hanipsych, functional recovery in depressionHanipsych, functional recovery in depression
Hanipsych, functional recovery in depression
 
MRCPsych Year 1 depression lecture sept 2013
MRCPsych Year 1 depression lecture sept 2013MRCPsych Year 1 depression lecture sept 2013
MRCPsych Year 1 depression lecture sept 2013
 
Hanipsych, biology of depression
Hanipsych, biology of depressionHanipsych, biology of depression
Hanipsych, biology of depression
 
Hanipsych, pain & dep
Hanipsych, pain & depHanipsych, pain & dep
Hanipsych, pain & dep
 
Considerazioni sulla terapia farmacologica per l'insonnia
Considerazioni sulla terapia farmacologica per l'insonniaConsiderazioni sulla terapia farmacologica per l'insonnia
Considerazioni sulla terapia farmacologica per l'insonnia
 
Depression in community
Depression in communityDepression in community
Depression in community
 
Vilazodone
VilazodoneVilazodone
Vilazodone
 
Henderson depression update incl tms
Henderson   depression update incl tmsHenderson   depression update incl tms
Henderson depression update incl tms
 
The neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolarThe neurobiology and pharmacotherapy of bipolar
The neurobiology and pharmacotherapy of bipolar
 
Different faces of depression
Different faces of depressionDifferent faces of depression
Different faces of depression
 
Schizophrenia
Schizophrenia Schizophrenia
Schizophrenia
 
Depression Clinical pharmacology
Depression Clinical pharmacologyDepression Clinical pharmacology
Depression Clinical pharmacology
 
Clever Nutrition can kick out depression
 Clever Nutrition can kick out depression Clever Nutrition can kick out depression
Clever Nutrition can kick out depression
 
The pharmacology of anti-depressants
The pharmacology of anti-depressants The pharmacology of anti-depressants
The pharmacology of anti-depressants
 
Treatment approach to resistant depression
Treatment approach to resistant depressionTreatment approach to resistant depression
Treatment approach to resistant depression
 
Bipolar disorder mrc psych
Bipolar disorder mrc psychBipolar disorder mrc psych
Bipolar disorder mrc psych
 
Hanipsych, resistant depression
Hanipsych, resistant depressionHanipsych, resistant depression
Hanipsych, resistant depression
 
Case # 29- The depressed man who thought he was out of options. .docx
Case # 29- The depressed man who thought he was out of options. .docxCase # 29- The depressed man who thought he was out of options. .docx
Case # 29- The depressed man who thought he was out of options. .docx
 

Mais de Rawalpindi Medical College (20)

Pertussis
PertussisPertussis
Pertussis
 
Nephrotic syndrome.
Nephrotic syndrome.Nephrotic syndrome.
Nephrotic syndrome.
 
Symptomtology of cardiovascular diseases
Symptomtology of cardiovascular diseasesSymptomtology of cardiovascular diseases
Symptomtology of cardiovascular diseases
 
Symptomatology-GIT-1
Symptomatology-GIT-1Symptomatology-GIT-1
Symptomatology-GIT-1
 
Symptomatology-GIT
Symptomatology-GITSymptomatology-GIT
Symptomatology-GIT
 
Symptomalogy in RENAL impairement
Symptomalogy in RENAL impairementSymptomalogy in RENAL impairement
Symptomalogy in RENAL impairement
 
History taking
History takingHistory taking
History taking
 
Right bundle branch block
Right bundle branch blockRight bundle branch block
Right bundle branch block
 
Right and left ventricular hypertrophy
Right and left ventricular hypertrophyRight and left ventricular hypertrophy
Right and left ventricular hypertrophy
 
Rheumatoid arthritis 2
Rheumatoid arthritis 2Rheumatoid arthritis 2
Rheumatoid arthritis 2
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Supraventricular tachyarrythmias
Supraventricular tachyarrythmiasSupraventricular tachyarrythmias
Supraventricular tachyarrythmias
 
Supraventricular tacchycardias
Supraventricular tacchycardias Supraventricular tacchycardias
Supraventricular tacchycardias
 
Skin-
Skin-Skin-
Skin-
 
Skin
Skin  Skin
Skin
 
Sick sinus syndrome-2
Sick sinus syndrome-2Sick sinus syndrome-2
Sick sinus syndrome-2
 
Sick sinus syndrome
Sick sinus syndrome Sick sinus syndrome
Sick sinus syndrome
 
X rays
X raysX rays
X rays
 
Ventricular arrhythmias
Ventricular arrhythmias Ventricular arrhythmias
Ventricular arrhythmias
 
Ventricular tachyarrhythmias
Ventricular tachyarrhythmias Ventricular tachyarrhythmias
Ventricular tachyarrhythmias
 

Último

Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptxmary850239
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
How to Filter Blank Lines in Odoo 17 Accounting
How to Filter Blank Lines in Odoo 17 AccountingHow to Filter Blank Lines in Odoo 17 Accounting
How to Filter Blank Lines in Odoo 17 AccountingCeline George
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
Latin American Revolutions, c. 1789-1830
Latin American Revolutions, c. 1789-1830Latin American Revolutions, c. 1789-1830
Latin American Revolutions, c. 1789-1830Dave Phillips
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 

Último (20)

Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx
3.19.24 Urban Uprisings and the Chicago Freedom Movement.pptx
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
How to Filter Blank Lines in Odoo 17 Accounting
How to Filter Blank Lines in Odoo 17 AccountingHow to Filter Blank Lines in Odoo 17 Accounting
How to Filter Blank Lines in Odoo 17 Accounting
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
Latin American Revolutions, c. 1789-1830
Latin American Revolutions, c. 1789-1830Latin American Revolutions, c. 1789-1830
Latin American Revolutions, c. 1789-1830
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 

Depression-2010

  • 1. Depressive Illness Asad Tamizuddin Nizami Assistant Professor Institute of Psychiatry Rawalpindi Medical College
  • 2. Major Depressive Episode A marked change from previous functioning for at least two weeks with 5 or more of the following symptoms: ▫ ▫ ▫ ▫ ▫ ▫ ▫ ▫ ▫ Depressed Mood (Irritability/anger in adolescents) Markedly diminished interest or pleasure Significant change in appetite and/or weight Insomnia or hypersomnia Psychomotor agitation or retardation Fatigue or loss of energy Feelings of worthlessness or excessive guilt Diminished concentration Recurrent thoughts of death
  • 3. Epidemiology • Depression is the fourth most important contributor to the global burden of disease • The point prevalence for depression is 1.9% for males and 3.2% for females. • 5.8% of males and 9.5% of females will develop a depressive episode within a 12-month period. • Every year 5-8% of the adult population gets a depression . • Lifetime risk for a severe depression amounts to 12-16%. Marianne C. Kastrup, Armando Báez Ramos . Global mental health- secondary publication Danish Medical Bulletin - No. 1. February 2007. Vol. 54 Pages 42-3
  • 4. In Pakistan…………. R a n d o m C o m m u n it y S a m p le 3 3 .6 2 % M en W om en 1 0 % (M u m fo rd 2 0 0 0 )- 3 3 % (J a v e d 1 9 9 4 ) 2 8 .8 % (R a b b a n i ) - 6 6 % (M u m fo rd 1 9 9 7 )
  • 5. Percentage of major diagnostic categories during four years in IOP journal of CPSP (2001)
  • 6. Etiology of Depression - Genetics • Indirect evidence suggests that the glycogen synthase kinase-3beta (GSK3beta) gene might be implicated in major depressive disorder (MDD). A recent study identified a link between the GSK3 beta polymorphism and the structural brain changes in major depressive disorder.(2) • A meta-analysis yielded little evidence that the serotonin transporter genotype alone or in interaction with stressful life events was associated with an elevated risk of depression in men alone, women alone, or in both sexes combined.(3) • • 2. Inkster B et al. Association of GSK3Beta polymorphism with structural brain changes in major depressive disorder. Arch Gen Psychiatry. 2009 Jul;66(7):721-8. 3. Risch N et al. JAMA. 2009 Jun 17;301(23):2462-71. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis.
  • 7. Neurobiology • In recent years the monoamine theory of depression has given way to a molecular and cellular theory that suggests that antidepressants work by increase in brain levels of neurotrophic factors such as brain-derived neurotrophic factor (BDNF). • Basic laboratory work has documented the importance of neurotrophins in neuronal survival and synaptic plasticity.which lead to structural brain changes i.e hippocampal atrophy seen in depression(1) Dan J. Stein, Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of Psychopathology
  • 8. Neurobiology • BNDF plays a role in a range of neurodegenerative, neuroinflammatory, and neurodevelopmental disorders, as well as in some psychiatric and substance use disorders. • Decreased hippocampal BDNF mRNA and cell atrophy are, for example, seen in several animal models of depression. • Depression is associated with decreased hippocampal volume, and depressed patients have decreased hippocampal BDNF. • Chronic stress leads to hippocampal cell loss and to downregulation of BDNF Dan J. Stein, Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of Psychopathology
  • 9. Interestingly………….. • In general practice 1 in 5 new consultations are for pain symptoms for which no specific cause is found. • The pain symptoms of 1/3 of all patients seen in medical clinics remain medically unexplained at the time of discharge.
  • 10. • • • • • • Research has indicated 34% of patients with joint or limb pain, 38% of patients with back pain, 40% of patients with headache, 46% of patients with chest pain, and 43% of patients with abdominal pain had Depression. Kroenke K, Spitzer RL, Williams JB, et al. Arch Fam Med. 1994;3:774-779.
  • 11. In primary care, physical symptoms are often the chief complaint in depressed patients In one study 69% of diagnosed depressed patients reported unexplained physical symptoms as their chief compliant1 N = 1146 Primary care patients with major depression 1. Simon GE, et al. N Engl J Med. 1999;341(18):1329-1335.
  • 12. Is there a connection between pain & depression…….. • There is a Neurochemical overlapping in the phenomena of pain complaints and depression. • Serotonin (or 5-HT) and norepinephrine have emerged as 2 neurotransmitters that are involved in both pain and depression.
  • 13. Both serotonin and nor epinephrine mediate a broad spectrum of depressive symptoms Serotonin (5-HT) Depressed Mood Norepinephrine (NE) Sex Anxiety Concentration Appetite Vague Aches and pain Interest Aggression Irritability Motivation Thought process References: 1. Adapted from: Stahl SM. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications: 2nd ed. Cambridge University Press 2000. 2. Blier P, et al. J Psychiatry Neurosci. 2001;26(1):37-43. 3. Doraiswamy PM. J Clin Psychiatry. 2001;62(suppl 12):30-35. 4. Verma S, et al. Int Rev Psychiatry. 2000;12:103-114.
  • 14. Serotonin5HT and Nor epinephrineNE in the brain Limbic System Prefrontal Cortex Raphe Nuclei (5-HT source) Cooper JR, Bloom FE. The Biochemical Basis of Neuropharmacology. 1996. Locus Ceruleus (NE Source)
  • 15. • Dysregulation of Serotonin (5HT) and Norepinephrine (NE) in the brain are strongly associated with depression • Dysregulation of 5HT and NE in the spinal cord may explain an increased pain perception among depressed patients1-3 • Imbalances of 5HT and NE may explain the presence of both emotional and physical symptoms of depression. Adapted from References: 1. Stahl SM. J. Clin Psych. 2002;63:203-220. 2. Verma S, et al. Int Rev Psychiatry. 2000;12:103-114. 3. Blier P, et al. J Psychiatry Neurosci. 2001;26(1):37-43. Descending Pathway Descending Pathway Ascending Pathway Ascending Pathway
  • 16. Research suggests that unexplained pain can be the best indicator of depression, especially among the elderly. Stewart RB, Blashfield R, Hale WE, et al. J Fam Pract. 1991;32:497-502.
  • 17. Ongoing untreated somatic depression lead to structural changes in the central nervous system and augments the risk of persistent pain’’
  • 18. Areas of the brain which are involved in memory and decision making undergo structural changes due to stress, which cause long term imbalances in hormonal regulation”
  • 19. • Hippocampus • Prefrontal cortex • Amygdala Undergo changes in size and function in depression
  • 20. • Dentate gyrus continues to produce new neurons in adult life • this is suppressed by acute and chronic stress and • restored by antidepressant treatment
  • 21. The loss of neurons in hippocampus due to stress is reversible if the stress is terminated at the end of 3 weeks Stress also suppresses neurogenesis and causes dendritic shrinkage
  • 22. Comorbid Mood and Anxiety Disorders Lifetime Comorbidity of Patients with PTSD1 48% to 65% of Patients 50% with Panic Disorder2 Posttraumatic Stress Disorder Social Phobia Panic Disorder Major Depression GAD (Social Anxiety Disorder) OCD of Patients with 34-70% Social Phobia4,6 of 39%-8% Patients with GAD5 of Patients 67% with OCD3 Kessler et al. Arch Gen Psychiatry, 1995 2. DSM-IV 3. Rasmussen.. 1 Psychopharmacol Bull, 1988 4. Van Ameringen et al. J Affect Disord, 1991 5. Brawman-Mintzer, Lydiard RB. J Clin Psychiatry, 1996 6. Stein et al, Am J Psychiatry, 2000
  • 23. Aims Of Treatment TREATMENT REDUCE SIGNS, SYMPTOMS RESTORE ROLE FUNCTION MINIMIZE RELAPSE/RECURREN CE RISK
  • 24. Treatment Options • Antidepressants • Combination Therapies • Psychotherapy • ECT
  • 25. STEPS: Antidepressant Selection • Safety Drug-drug interaction potential • Tolerability Acute and long term • Efficacy Onset of action Treatment and prophylaxis • Payment Cost-effectiveness • Simplicity Dosing Need for monitoring
  • 26. Antidepressants Groups • TCAs : Amitriptyline, Doxepine, Trimipramine, Clomipramine and other. • SSRI : Fluvoxamine, Fluoxetine, Paroxetine, Sertraline, Citalopram, Escitalopram • RIMA :(Reversible inhibitor of MAO type A) Moclobemide • SNRI : (Reuptake inhibition of NA/5-HT ) Venlafaxine
  • 27. Antidepressants Groups • NaSSA : (5-HT2 and 5-HT3 antagonist,H1 antagonist.) Mirtazapine • DSA : (5-HT2 antagonist and 5-HT reuptake inhibitor) Nefazodone • NARI (SNRI) : (Selective NA reuptake inhibitor) Reboxetine
  • 28. Adverse events—a significant cause of treatment discontinuation Poor tolerability in early therapy Drop out of SSRI therapy Lin EHB et al. Medical Care 1995; 33:67–74. Maddox JC et al. J Psychopharmacol 1994; 8:48–53.
  • 29. Early drop out – other evidence • Early drop out is common among patients taking antidepressants: ▫ 28% by week 4* ▫ 43% by week 8* ▫ 52% by week 12* * Maddox JC et al. J Psychopharmacol 1994; 8:48-53
  • 30. Adverse Events Are A Major Cause of Early Dropout with SSRI Treatment Most common early adverse events resulting in dropouts (> 5%) Nausea Headache Anxiety Drowsiness N = 672; SSRIs included paroxetine or fluoxetine Bull SA, et al. Ann Pharmacother. 2002;36:578–584.
  • 31. Nausea is one of the most common side effects • SSRIs have been associated with early GI adverse events, resulting in: ▫ poor compliance ▫ compromised long-term efficacy ▫ premature termination of treatment1,2 • Nausea is a leading cause of premature treatment discontinuation for the SSRIs and serotonin norepinephrine reuptake inhibitors3 • Clinical trials in major depression with paroxetine IR (n = 6145) ▫ most common event associated with withdrawal on paroxetine IR was nausea (3.2% vs. 1.1% on placebo). • Paroxetine CR was developed to minimise early-onset nausea through a shifting of the drug absorption site (lower in GI tract) 1 Lin EHB et al. Medical Care 1995; 33:67–74. 2 Maddox JC et al. J Psychopharmacol 1994; 8:48–53. 3 Golden RN et al. J Clin Psychiatry 2002; 63:577-584
  • 32. Summary • Patients have a high rate of non-adherence with SSRIs due to adverse events • First few weeks of therapy are critical • Monitor medication compliance during this time period • Choose a medication that is effective and generally well tolerated across multiple indications
  • 33. Role of Psychotherapy? • Psychotherapy either alone or in combination with medication, has been shown to be effective in the treatment of comorbid pain and depression • Some studies have found that the combination of medical and psychotherapeutic treatments provides better results than medication alone. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Arch Gen Psychiatry. 1984;41:33-41.

Notas do Editor

  1. Some symptoms (e.g. appetite, attention) seem to be mediated more by one neurotransmitter than the other. Some other symptoms (e.g. anxiety) seem to be mediated by either. There are other symptoms (e.g. aches and pain) that seem to be mediated more consistently by a combination of both the neurotransmitters.
  2. Serotonin and Norepinephrine in Depression1 Serotonin and norepinephrine are believed to be key neurotransmitters in the etiology of depression From the raphe nuclei and locus ceruleus, 5-HT and NE, respectively, send projections up to the prefrontal cortex and limbic system where emotional depressive symptoms are thought to be mediated. Additionally, there are also 5-HT and NE-rich tracts into the spinal cord, which are thought to modulate pain perception. 1. Adapted from Stahl SM. J Clin Psych. 2002; 63: 382-383.
  3. DEPRESSIVE DISORDERS: AIMS OF TREATMENT Once depressive disorders are diagnose, the initial objectives of treatment, in order of priority are to: Reduce & ultimately remove all signs and symptoms of the depressive disorder. Restore occupational and psychosocial roles/functions to the asymptomatic state. Minimize the risk of relapse and recurrence.
  4. Nonadherence to antidepressant therapy is a major obstacle in the effective treatment of anxiety disorders and depression. A study by Maddox, et al, that analysed dropout rates over a 12-week period in patients who were prescribed antidepressant agents revealed that 52% of patients had discontinued their medication at the 10–12-week period; of these patients, 58% had dropped out due to adverse events. Over one half of patients who dropped out reported that their physicians did not know they had stopped their therapy. As might be expected, the worse the side effects, the less time for which the patient will take their medications, suggesting that the occurrence of side effects is an important reason for noncompliance.
  5. Adverse events have been the leading reason patients do not comply with their SSRI therapy. Compliance improves if patient receives an effective medication and is informed of targeted duration of therapy. In one large scale study examining adherence to antidepressant therapy, 43% of patients who stopped their treatment prematurely did so as a result of adverse events. The most common early adverse events resulting in dropouts were nausea, headache, drowsiness, and an increased feeling of anxiety. Reference Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578–584.
  6. As previously discussed, data from studies by Lin, et al and Maddox, et al suggest that adverse events reported with antidepressant therapy are associated with poor compliance, compromised long-term efficacy and premature termination of treatment. Thus, the rationale for the development of Seroxat/Paxil CR was to minimise early-onset nausea in order to help improve compliance and reduce premature termination of treatment.
  7. We hope that this presentation will support you in being even more successful in your important efforts to help persons who suffer from depression and associated anxiety symptoms.